Evidence map›Paper›PMID 42633178›Full record

ArticleiScience2026

HopRatio: Profiling single-sample transcriptomic dysregulation using stable gene-ordering relationships.

Yue Zhao, Bo Gao, Rui Chen

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yue ZhaoSchool of Public Health, Capital Medical University, Beijing 100069, P.R. China.
Bo GaoSchool of Public Health, Capital Medical University, Beijing 100069, P.R. China.
Rui ChenSchool of Public Health, Capital Medical University, Beijing 100069, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-sample transcriptomic analysis can provide gene-level views of how individual tumors deviate from matched reference states, complementing cohort-level differential expression. Here, we present HopRatio, a rank-based framework that quantifies, for each gene in each sample, the fraction of stable reference gene-ordering relationships inverted relative to a context-matched reference cohort. By relying on within-sample ranks rather than cross-sample expression magnitudes, HopRatio enables sample-specific scoring without cross-sample normalization for score calculation. Across 16 cancer types from The Cancer Genome Atlas with tissue-matched Genotype-Tissue Expression references, HopRatio generated individualized dysregulation profiles that supported tumor-normal discrimination using single genes and compact multi-gene panels. Recurrent high-performing features defined a 246-gene set enriched for developmental, membrane-associated, and ion-transport programs and associated with poor survival across cancers. Benchmarking in the Sequencing Quality Control dataset supported its robustness relative to commonly used differential expression methods, highlighting a scalable route for interpretable individualized transcriptomic analysis.

Indexed as

cancer biomarkersHopRatioprecision oncologyrank-based disruptionsingle-sample transcriptomics

Identifiers

PMID42633178
PMCPMC13499136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.